You are here

Argenx

Biotech Argenx's autoimmune phase 3 hits goals, teeing up FDA filing

Biotech Argenx's autoimmune phase 3 hits goals, teeing up FDA filing

Fierce Biotech

myasthenia gravis

Flag link:

Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous

Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous

EP Vantage

Wave Life Sciences

Huntington's disease

autoimmune disease

Flag link:

Argenx and Halozyme Ink Multiple Target Deal That Could Hit $540 Million

Argenx and Halozyme Ink Multiple Target Deal That Could Hit $540 Million

BioSpace

Halozyme Therapeutics

drug development

Flag link:

Should You Be Worried About the Return of Big Pharma Deals?

Should You Be Worried About the Return of Big Pharma Deals?

Motley Fool

Flag link:

ASH18: Argenx pens $1.6B biobucks Janssen pact for blood cancer hopeful cusatuzumab

ASH18: Argenx pens $1.6B biobucks Janssen pact for blood cancer hopeful cusatuzumab

Fierce Biotech

Flag link:

Argenx To Raise $300 million in U.S. public offering

Argenx To Raise $300 million in U.S. public offering

CP Wire

Flag link:

AbbVie doubles down on cancer project with biotech group Argenx

AbbVie doubles down on cancer project with biotech group Argenx

Yahoo/Reuters

cancer immunotherapy

Flag link:

Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug

Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug

CP Wire

Flag link:

Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug

Flag link:

Argenx IPO haul tops out at $115M, 50% above initial goal

Argenx IPO haul tops out at $115M, 50% above initial goal

Fierce Biotech

Flag link:

AbbVie Strikes Two Cancer Collaborations: Smart Move?

AbbVie Strikes Two Cancer Collaborations: Smart Move?

Bidness, ETC

Flag link: